From Dr Reddys website:SEGMENTAL ANALYSISGlobal GenericsRevenues...

From Dr Reddys website:


SEGMENTAL ANALYSIS

Global Generics
Revenues from Global Generics segment for FY13 are at Rs.82.6 billion with a year-on-year growth of 18%, primarily driven by North America and Emerging Markets.

Revenues from North America for FY13 at Rs.37.8 billion, recorded year-on-year growth of 19%. Excluding the beneficial impact of olanzapine exclusivity in FY12, registered year-on-year growth of 38%.
Growth is largely driven by key limited competition products such as ziprasidone, fondaparinux, ramp-up in our antibiotics portfolio and products from our Shreveport facility.
Significant contribution from new products launched during the year. 14 new products have been launched during the year major contributors being finasteride 1mg (180 day exclusivity), montelukast granules, atorvastatin, metoprolol, clopidogrel, ibandronate and zoledronic acid 4mg/5mL.
19 product filings (18 ANDAs and 1 NDA). Cumulatively, 65 ANDAs are pending for approval with the USFDA of which 38 are Para IVs and 8 have ‘First To File’ status.